 Hematologic Neoplasms
"Hematologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Descriptor ID |
D019337
|
| MeSH Number(s) |
C04.588.448 C15.378.400
|
| Concept/Terms |
Hematologic Neoplasms- Hematologic Neoplasms
- Malignancies, Hematologic
- Malignancy, Hematologic
- Hematological Neoplasms
- Hematological Neoplasm
- Neoplasm, Hematological
- Neoplasms, Hematological
- Neoplasms, Hematologic
- Hematologic Neoplasm
- Neoplasm, Hematologic
- Hematological Malignancies
- Hematological Malignancy
- Malignancies, Hematological
- Malignancy, Hematological
- Hematologic Malignancy
- Hematologic Malignancies
Hematopoietic Neoplasms- Hematopoietic Neoplasms
- Hematopoietic Malignancies
- Hematopoietic Malignancy
- Malignancies, Hematopoietic
- Malignancy, Hematopoietic
- Neoplasms, Hematopoietic
- Hematopoietic Neoplasm
- Neoplasm, Hematopoietic
|
Below are MeSH descriptors whose meaning is more general than "Hematologic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Hematologic Neoplasms".
This graph shows the total number of publications written about "Hematologic Neoplasms" by people in UAMS Profiles by year, and whether "Hematologic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 3 | 0 | 3 | | 2021 | 8 | 0 | 8 | | 2020 | 2 | 1 | 3 | | 2019 | 2 | 1 | 3 | | 2018 | 2 | 1 | 3 | | 2017 | 2 | 1 | 3 | | 2016 | 1 | 1 | 2 | | 2015 | 3 | 1 | 4 | | 2014 | 3 | 1 | 4 | | 2012 | 2 | 0 | 2 | | 2011 | 1 | 0 | 1 | | 2009 | 1 | 2 | 3 | | 2008 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2006 | 2 | 0 | 2 | | 2005 | 0 | 1 | 1 | | 2004 | 2 | 0 | 2 | | 2003 | 3 | 0 | 3 | | 2002 | 2 | 0 | 2 | | 1997 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hematologic Neoplasms" by people in Profiles over the past ten years.
-
Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, Chung DJ, Doddi S, Falchi L, Gyurkocza B, Hamilton A, Lin YH, Jakubowski AA, Joffe E, Landau HL, Lin RJ, Mailankody S, Palomba ML, Park JH, Perales MA, Ponce DM, Ramanathan LV, Salles GA, Scordo M, Seo SK, Shah UA, Stein EM, Straus D, Usmani SZ, Young JW, Zelenetz AD, Noy A, Vardhana SA. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022 Jun 13; 40(6):590-591.
-
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
-
Alagpulinsa DA, Toribio MP, Alhallak I, Shmookler Reis RJ. Advances in understanding the molecular basis of clonal hematopoiesis. Trends Mol Med. 2022 05; 28(5):360-377.
-
Lopez-Candales A, Mathur P, Mounsey JP, Veeraputhiran M. Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant? Postgrad Med. 2022 Jan; 134(1):7-10.
-
Al Hadidi S, Kamble RT, Carrum G, Heslop HE, Ramos CA. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Adv. 2021 11 23; 5(22):4630-4633.
-
Bonafede M, Anaissie E, Evans K, Itzler R. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis. BMC Health Serv Res. 2021 Oct 20; 21(1):1125.
-
Ribas A, Dhodapkar MV, Campbell KM, Davies FE, Gore SD, Levy R, Greenberger LM. How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. Blood Cancer Discov. 2021 11; 2(6):562-567.
-
Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, Lai YR, Liu DH, Liu QF, Liu T, Ren HY, Song YP, Sun ZM, Tang XW, Wang JM, Wu DP, Xu LP, Zhang X, Zhou DB, Huang XJ. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021 09 15; 14(1):145.
-
Niu A, Ning B, Socola F, Safah H, Reynolds T, Ibrahim M, Safa F, Alfonso T, Luk A, Mushatt DM, Hu T, Saba NS. High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies. Leuk Res. 2021 07; 106:106582.
-
Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.
-
Ibrahim M, Vegel A, Niu A, Panse K, Chen R, Safah H, Socola F, Luk A, Saba NS. Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. Leuk Res. 2021 02; 101:106514.
-
Taylor J, Donoghue MT, Ho C, Petrova-Drus K, Al-Ahmadie HA, Funt SA, Zhang Y, Aypar U, Rao P, Chavan SS, Haddadin M, Tamari R, Giralt S, Tallman MS, Rampal RK, Baez P, Kappagantula R, Kosuri S, Dogan A, Tickoo SK, Reuter VE, Bosl GJ, Iacobuzio-Donahue CA, Solit DB, Taylor BS, Feldman DR, Abdel-Wahab O. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest. 2020 12 01; 130(12):6668-6676.
-
Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Meyer RE, Canfield MA, Rasmussen SA, Chambers TM, Spector LG, Plon SE, Lupo PJ. Cancer diagnostic profile in children with structural birth defects: An assessment in 15,000 childhood cancer cases. Cancer. 2020 08 01; 126(15):3483-3492.
-
Atrash S, Bano K, Harrison B, Abdallah AO. CAR-T treatment for hematological malignancies. J Investig Med. 2020 06; 68(5):956-964.
-
Kim J, Park J, Lee MO, Park EY, Heo S, Shim JL. Modifiable Factors Associated with the Completion of Advance Treatment Directives in Hematologic Malignancy: A Patient-Caregiver Dyadic Analysis. J Palliat Med. 2020 05; 23(5):611-618.
-
Pandey S, Gokden M, Kazemi NJ, Post GR. Hematolymphoid Malignancies Presenting with Spinal Epidural Mass and Spinal Cord Compression: A Case Series with Rare Entities. Ann Clin Lab Sci. 2019 Nov; 49(6):818-828.
-
Inagaki K, Blackshear C, Hobbs CV. Pneumocystis Infection in Children: National Trends and Characteristics in the United States, 1997-2012. Pediatr Infect Dis J. 2019 03; 38(3):241-247.
-
Onyeama SN, Hanson SJ, Dasgupta M, Baker K, Simpson PM, Punzalan RC. Central Venous Catheter-associated Venous Thromboembolism in Children With Hematologic Malignancy. J Pediatr Hematol Oncol. 2018 11; 40(8):e519-e524.
-
Ahmed J, Karass M, Aujla A, McHale P, Kretschmer P, Mazumder A, Seiter K, Ahmed T, Lim SH, Knoll BM. Late-onset fever and engraftment syndrome following autologous stem cell transplant: Impact on resource utilization. Am J Hematol. 2018 10; 93(10):E336-E338.
-
Pina-Oviedo S, Miranda RN, Medeiros LJ. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder. Am J Surg Pathol. 2018 Jan; 42(1):116-129.
-
King J, Pana ZD, Lehrnbecher T, Steinbach WJ, Warris A. Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. J Pediatric Infect Dis Soc. 2017 Sep 01; 6(suppl_1):S12-S21.
-
Morgan GJ, Rasche L. Haematological cancer: Where are we now with the treatment of multiple myeloma? Nat Rev Clin Oncol. 2017 08; 14(8):461-462.
-
Bommagani S, Ponder J, Penthala NR, Janganati V, Jordan CT, Borrelli MJ, Crooks PA. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. Eur J Med Chem. 2017 Aug 18; 136:393-405.
-
Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, Miligi L, Beane Freeman LE, de Sanjose S, Bernstein L, Monnereau A, Clavel J, Tricot GJ, Atanackovic D, Cocco P, Orsi L, Dosman JA, McLaughlin JR, Purdue MP, Cozen W, Spinelli JJ, de Roos AJ. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. Br J Haematol. 2016 Oct; 175(1):87-101.
-
Liu YL, Yan Y, Webster C, Shao L, Lensing SY, Ni H, Feng W, Colorado N, Pathak R, Xiang Z, Hauer-Jensen M, Li S, Zhou D, Emanuel PD. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. Blood. 2016 Apr 14; 127(15):1912-22.
-
Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR, Crooks PA. Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. J Med Chem. 2015 Nov 25; 58(22):8896-906.
-
Mathur P, Paydak H, Thanendrarajan S, van Rhee F. Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):70-5.
-
Nouér SA, Nucci M, Anaissie E. Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant Gram-negative organisms. Expert Rev Hematol. 2015 Oct; 8(5):647-58.
-
Zhan F, Zangari M, Qiu L. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics. Biomed Res Int. 2015; 2015:384575.
-
Morgan GJ, van Rhee F. Haematological cancer: Optimizing the treatment of multiple myeloma. Nat Rev Clin Oncol. 2014 Dec; 11(12):686-8.
-
Chemaly RF, Ghantoji SS, Shah DP, Shah JN, El Taoum KK, Champlin RE, Nunez CA, Mulanovich V, Ariza-Heredia E. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol. 2014 Aug; 36(6):e376-81.
-
Wang L, Zhang H, Rodriguez S, Cao L, Parish J, Mumaw C, Zollman A, Kamoka MM, Mu J, Chen DZ, Srour EF, Chitteti BR, HogenEsch H, Tu X, Bellido TM, Boswell HS, Manshouri T, Verstovsek S, Yoder MC, Kapur R, Cardoso AA, Carlesso N. Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-?B-dependent manner. Cell Stem Cell. 2014 Jul 03; 15(1):51-65.
-
Veeraputhiran M, Jain T, Cronin S, Al-Kadhimi Z, Abidi MH, Ayash L, Mellert K, Lum LG, Ratanatharathorn V, Uberti JP, Deol A. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. J Clin Apher. 2014 Dec; 29(6):293-8.
-
Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, McNamara L, Evans SO, Riley U, Davies FE, Dearden CE, Morgan GJ, Shaw BE. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. Clin Transplant. 2013 Jan-Feb; 27(1):E56-63.
-
Insuasti-Beltran G, Steidler NL, Kang H, Reichard KK. CD34+ megakaryocytes (=30%) are associated with megaloblastic anaemia and non-acute myeloid neoplasia. Histopathology. 2012 Oct; 61(4):694-701.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|